BrainsWay (NASDAQ:BWAY) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BrainsWay (NASDAQ:BWAYFree Report) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $15.00 price target on the stock.

Separately, Oppenheimer raised their target price on shares of BrainsWay from $10.00 to $11.00 and gave the company an outperform rating in a research report on Thursday, May 9th.

Get Our Latest Stock Analysis on BrainsWay

BrainsWay Stock Up 2.9 %

Shares of BWAY stock opened at $7.08 on Wednesday. The firm has a fifty day moving average of $5.47 and a 200-day moving average of $5.95. BrainsWay has a 12-month low of $1.97 and a 12-month high of $7.61. The company has a market capitalization of $117.88 million, a price-to-earnings ratio of -54.46 and a beta of 1.23.

BrainsWay (NASDAQ:BWAYGet Free Report) last released its earnings results on Wednesday, March 6th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The business had revenue of $9.03 million during the quarter, compared to the consensus estimate of $8.40 million. BrainsWay had a negative net margin of 4.83% and a negative return on equity of 3.98%. During the same quarter last year, the firm earned ($0.12) earnings per share. On average, equities analysts expect that BrainsWay will post 0.01 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. AIGH Capital Management LLC grew its position in shares of BrainsWay by 6.5% in the 3rd quarter. AIGH Capital Management LLC now owns 1,355,022 shares of the company’s stock valued at $5,474,000 after acquiring an additional 83,262 shares during the period. Worth Venture Partners LLC grew its position in shares of BrainsWay by 6.0% in the 3rd quarter. Worth Venture Partners LLC now owns 336,643 shares of the company’s stock valued at $1,360,000 after acquiring an additional 19,045 shares during the period. Essex Investment Management Co. LLC grew its position in shares of BrainsWay by 37.5% in the 1st quarter. Essex Investment Management Co. LLC now owns 324,843 shares of the company’s stock valued at $1,718,000 after acquiring an additional 88,593 shares during the period. Acadian Asset Management LLC grew its position in shares of BrainsWay by 583.2% in the 1st quarter. Acadian Asset Management LLC now owns 175,416 shares of the company’s stock valued at $923,000 after acquiring an additional 149,740 shares during the period. Finally, Legato Capital Management LLC bought a new position in shares of BrainsWay in the 4th quarter valued at about $542,000. Institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

(Get Free Report)

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

See Also

Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.